Sahajanand Medical Technologies Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Sahajanand Medical Technologies Limited's is preparing to launch its Initial Public Offering (IPO) with a substantial issue size of 2,76,44,231 Shares. The offering comprises a fresh issue component of TBD.
The price band for the IPO has been set at TBD, providing investors with a range to place their bids. The minimum investment lot consists of TBD, making it accessible to both retail and institutional investors.
The subscription window for this public offering opens on TBD and will conclude on TBD. Following the subscription period, the share allotment is scheduled for TBD, with the official listing expected to commence on TBD on the NSE, BSE exchange.
Founded in 2001 by Mr. Dhirajlal Kotadia, Sahajanand Medical Technologies Ltd. is a medical device company that focuses on advanced Class III and Class C/D devices used mainly in vascular and structural heart treatments. The company was the first in the world to receive CE certification for a drug-eluting stent with a biodegradable polymer called Infinnium. Its product range includes coronary stents and balloons for vascular interventions, technologies like TAVI and occluders for structural heart treatments, as well as renal stents and drug-coated balloons. The company operates R&D centres in India and Thailand and has a strong innovation base with over 100 granted patents and several pending applications. Its key products, including Supraflex Cruz, Hydra, and Cocoon, are supported by multiple clinical studies and are used in more than 76 countries. Sahajanand follows a global distribution strategy combining direct sales, hybrid models, and distributor partnerships across different markets. As of March 31, 2025, the company had over 1,400 employees along with consultants and contract staff supporting its operations.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
The expected premium (GMP) is based on market buzz and unofficial trading. It should not be considered as the guaranteed listing price. Always refer to the RHP and seek advice from a financial expert before making investment decisions.
💡 Read our detailed guide: What is IPO Grey Market Premium (GMP) & How It Works?
- Strong R&D and Innovation Focus: Company advanced medical devices develop kare che (stents, heart valves etc.), je strong research capability ane innovation strength darshave che.
- Global Presence & Export Market: Products 70+ countries ma use thay che, je thi business ne international diversification ane scale male che.
- Recurring Demand Medical Segment: Stents ane consumables jeva products ni continuous demand hoy che, je stable long-term revenue support kare che.
- High Competition in Medical Devices: Global players sathe tough competition hoy che, je pricing ane margins par pressure kare che.
- Regulatory Dependency Risk: Healthcare industry ma approvals ane regulations strict hoy che, je product launches ane expansion slow kari shake che.
- Customer Concentration Risk: Hospital chains ane government procurement par reliance hoy to order flow uneven thai shake che.
- Bhargav Dhirajlal Kotadia
- Dhirajlal Vallabhbhai Kotadia
- Priyanka Dhirajlal Cohen
- Shree Hari Trust
Sahajanand Medical Technologies Limited
Link Intime India Private Limited